Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Pharvaris - The Untold Story

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Pharvaris N.V. (NASDAQ:PHVS) on Wednesday shared topline data from the RAPIDe-3 Phase 3 trial of deucrictibant for the on-demand treatment of hereditary angioedema (HAE) attacks.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2022

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022

Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.